Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what processes are in place to ensure that patients are able to continue on their existing haemophilia treatments regardless of the outcome of the NHS England tender for Factor IX haemophilia treatments.

Patients for whom NHS England has commissioning responsibility will have access to treatments which are successful in their application to the upcoming Factor IX tender. Whilst there are no immediate plans for product switching, NHS England will continue to seek to optimise the value offered by all tenders which impact on healthcare budgets.